Dr Walid Zaher is the Chief Executive Officer at IROS and also the Chief Research Officer at G42 Healthcare. He has been the Vaccine project Lead including Phase-III clinical trials of the Sinopharm inactivated vaccine against COVID-19.

Before joining G42 Healthcare, Dr Walid was Corporate Group Clinical Research & Innovation Director at Abu Dhabi Health Services Company [SEHA]. He is also an adjunct Associate Professor at the college of medicine at UAE University and Khalifa University.

Before his UAE stint, Dr Walid was the Director of the College of Medicine Research Centers and an assistant professor of regenerative medicine and stem cells at King Saud University in Riyadh. He has been a consultant for Saudi 2020 National Biotechnology and Infectious Disease plan at KASCT.

He graduated with a Bachelor of Medicine and Surgery and Master’s in Medical Education, Anatomy and Embryology, and Bioscience Technology from Saudi Arabia. He completed his PhD in Regenerative Medicine from Denmark, and laser-medicine applications training at Harvard-MGH, Boston.